Food-Drug Interactions Could be Impactful for Some Lung Cancer Patients According to New Study in JNCCN
National Comprehensive Cancer Network® (NCCN®)New research in the June 2023 issue of JNCCN—Journal of the National Comprehensive Cancer Network found that when alectinib—a safe and effective small molecule kinase inhibitor used to treat some types of advanced lung cancer—was taken with a fuller breakfast, or with lunch, it resulted in significantly higher drug concentrations than when taken with a low-fat breakfast.